Signet Therapeutics receives FDA approval for sigx1094 IND application
This marks a significant advancement as sigx1094 is the world’s first targeted therapy for DGC, a condition with a notable lack of effective treatments. The company is set
Alembic Pharmaceuticals has announced its tentative approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) submitted for Ivosidenib Tablets, 250mg.
New investors Mubadala Capital and Exor Ventures spearheaded this oversubscribed round. The Series B extension also saw participation from Qatar Investment Authority, alongside current stakeholders including Abingworth and